MIR MedMira Inc

HALIFAX, Feb. 2, 2012 /CNW/ - MedMira Inc., (MedMira) , a developer and marketer of rapid diagnostic technology and solutions, today announced that the Company's Board of Directors was elected at MedMira's 2012 Annual General and Special Meeting of Shareholders, which was held on January 30th, 2012. Mr. Hermes Chan, Dr. Shou-Ching Tang, Mr. Romano Robusto and Mr. Markus Meile were re-elected as directors of the Company. "MedMira's Board of Directors provides strategic insight and direction on business execution to the Company's management team as it moves forward on key strategies for 2012," said Hermes Chan, CEO and Director, MedMira.  "The Company is committed to positioning itself for growth by building on success, including China market penetration and the US Army contract.  MedMira will transform structurally into distinct and focused business units, implement automation in its manufacturing processes, and restore its financial condition.  Most importantly, we will continue to innovate, bringing new products to market and building our brand in high growth niche markets." Shareholders approved all other matters considered at the meeting including the appointment of Deloitte & Touche LLP as the Company's auditors and ratification of the stock option plan. About MedMira MedMira is a leading developer and manufacturer of flow-through rapid diagnostics and technologies. The Company's tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis of infectious diseases. MedMira diagnostics are sold under the Reveal®, MiraWell®, Multiplo™, and Miriad brands in global markets. MedMira's rapid HIV test is the only rapid HIV test in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira's website at www.medmira.com. This news release contains forward-looking statements, including statements regarding development of sales opportunities, which involve risk and uncertainties and reflect the company's current expectation regarding future events.  Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement. MEDMIRA INC. CONTACT: MedMira Contact: Andrea YoungT. 902-450-1588E. ayoung@medmira.com

Copyright